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To seek for a candidate gene that would regulate tumour progression and metastasis in gastric cancer, we investigated gene
expression profiles by using DNA microarray. Tumour tissue and adjacent normal tissue were obtained from 21 patients with gastric
cancer and then examined for their gene expression profiles by the Gene Chip
s Human U95Av2 array, which includes 12000
human genes and EST sequences. A total of 25 genes were upregulated and two genes were downregulated by at least four-fold in
the tumour tissue. In a further analysis according to lymph node metastasis, the expressed levels of maspin, as well as
carcinoembryonic antigen and nonspecific crossreacting antigen were significantly higher in tumours with lymph node metastasis than
in those without it. Maspin expression in 85 gastric cancer patients was further investigated by using immunohistochemistry. Maspin
expression was not observed in normal gastric epithelia without intestinal metaplasia. In contrast, maspin was expressed in 74 of 85
tumour tissues. There was a significant correlation between the incidence of maspin-positive tumour staining and lymph node
metastasis. These results suggest that maspin has a potential role for tumour metastasis in gastric cancer.
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The incidence of gastric cancer has been gradually declining in
developed countries; however, gastric cancer is still the most
common cancer in Eastern Asia, Eastern Europe, and South
America and is the second leading cause of cancer deaths in the
world (Pisani et al, 1999). For the treatment of gastric cancer,
several modalities are performed such as surgery, chemotherapy,
radiotherapy, and immunotherapy. Among them, surgery is the
most comprehensive and reliable procedure to cure the disease,
especially when it is localised. Nevertheless, the operative results
for advanced gastric cancer remain unsatisfactory even when
extensive surgery had been performed (Roukos, 2000). To improve
the therapeutic results for gastric cancer, the exploration of genes
related to metastasis and elucidation of the mechanism of tumour
progression are considered to be of great importance. For this
purpose, numerous molecular biological studies have been carried
out, and several genetic and epigenetic alterations have been
clarified for carcinogenesis and progression of gastric cancer.
Inactivation of tumour suppressor genes such as p53, DCC, APC,
and E-cadherin and amplification of oncogenes, including K-ras,
beta-catenin, c-erbB-2, K-sam, cyclin E, and c-MET, are frequently
observed in gastric cancer (Yasui et al, 2001). In addition, aberrant
DNA methylation of promoter region CpG islands has been
reported as a means for the inactivation of tumour suppressor or
tumour-related genes (Tamura et al, 2000; Tamura, 2002).
More recently, microarray technology has made it possible to
comprehensively analyse gene expression profiles (Hasegawa et al,
2002; Hippo et al, 2002; Inoue et al, 2002). By using this technique,
the expression levels of thousands of genes can be analysed in a
single experiment. This technology is a powerful tool for analysing
gene expression profiles related to the development and progres-
sion of specific diseases. Although there have been significant
improvements in the analysis of genetic alterations for gastric
cancer, there is still insufficient information for understanding a
common pathway for the development and progression of gastric
cancer. Gastric cancer has diverse clinical properties such as
histological type, metastatic status, race, and gender. Thus, further
exploration to search for genetic alterations in gastric cancer is
required.
In the present study, we performed oligonucleotide microarray
analysis representing more than 12000 unique genes to character-
ize the global gene expression profiles of gastric cancer tissues and
sought to identify specific gene sets that correlate with lymph node
metastasis.
From the microarray analysis, maspin was selected as one of the
genes upregulated in gastric cancer. We had previously investi-
gated the expression of maspin in gastric cancer and had reported
that maspin expression was observed in 80% of gastric cancer
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stissues and in all gastric normal epithelium with intestinal
metaplasia, but not in normal epithelium without intestinal
metaplasia, and that expression of maspin was regulated by
methylation at the CpG islands of the promoter region (Akiyama
et al, 2003). Son et al (2002) also reported that 90% of gastric
cancer tissue showed positive expression of maspin; however,
the role of maspin in the progression of gastric cancer has not
yet been elucidated. In the present study, we further investigated
the correlation of maspin expression and clinicopathologic
features with special reference to lymph node metastasis in gastric
cancer.
MATERIALS AND METHODS
Tissue samples for DNA microarray
For DNA microarray, 21 pairs of gastric cancer tissue and
corresponding gastric normal epithelium were obtained from a
total of 21 patients who underwent gastrectomy at Iwate Medical
University. Patient characteristics were determined according to
the Japanese classification of Gastric Carcinoma (2nd English
edition) (Japanese Gastric Cancer Association, 1998) and are listed
in Table 1. Permission of the Institutional Review Board (IRB) was
obtained (#H12-32, March 14, 2001), and written consent was
obtained from all patients prior to surgery. Primary gastric cancer
tissue and adjacent normal mucosa were carefully dissected
immediately after operation from surgically resected samples and
stored at  801C until used for analysis. Tissue sections for
histopathologic examination were made from the samples
obtained to evaluate the presence of cancer cells in the tumour
samples and the presence of intestinal metaplasia in the gastric
normal epithelium. Of 21 normal samples, 15 contained intestinal
metaplasia and were excluded from the normal controls. As a
result, six samples were provided as normal controls.
DNA microarray
A total of 21 gastric cancer tissues and six gastric normal epithelia
were lysed and total RNA was extracted by using the Sepasol-RNA
I (WAKO, Osaka, Japan) according to the manufacturer’s
instructions. The extracted total RNA was purified with an RNeasy
column (Qiagen, Austin, TX, USA). Affymetrix (Santa Clara, CA,
USA) microarray analysis was performed according to the
manufacturer’s instructions. Total RNA (5mg) was reverse
transcribed to cDNA by using the T7-(dT) 24 primer. Biotin-
labelled cRNA was synthesised from cDNA by using the MEGA
script In Vitro Transcription Kit (Ambion, Austin, TX, USA).
cRNA was fragmented to an average size of 50–100 nucleotides by
incubation at 951C for 35min in 40mM Tris-acetate (pH 8.1)
containing 100mM potassium acetate and 30mM magnesium
acetate, and then hybridisation to human GeneChip
s (Human
Genome Arrays U95Av2, Affymetrix) containing approximately
12000 human genes. This commercially available array has been
designed and used for quantitative and highly parallel measure-
ments of gene expression (Lipshutz et al, 1999). The hybridised
oligonucleotide microarrays were scanned with a confocal scanner
(Affymetrix). The scanned data obtained from each microarray
were normalised by the All Probe Set Normalization method,
which adjusted the trimmed mean signal of the experiment to a
global intensity of 300 units, to correct for small differences in the
amounts of each cRNA probe applied to the microarray and were
processed for average difference values by using Affymetrix
software (LIMS 5.0). Fold level changes of gene expression in
gastric carcinoma were calculated by comparison with the pooled
data of six independent normal tissues.
Real-time quantitative reverse transcription–polymerase
chain reaction (RT–PCR) (RQ-PCR)
For RQ-PCR assay, the primers and fluorogenic probe were
designed with Primer Express software (ABI): maspin F (nucleo-
tides 646–665; 50-CGA CCA GAC CAA AAT CCT TG-30), maspin R
(nucleotides 778–796; 50-GAA CGT GGC CTC CAT GTT C-30),
probe (nucleotides 745–772; 50-FAM-CAA CAA GAC AGA CAC
CAA ACC AGT GCA G-TAMURA-30). For RQ-PCR assay, an ABI
PRISM7000 sequence Detector (ABI) was used. The reaction mix
contained 50ng of cDNA, 200nmoll
 1 of each primer, 5mmoll
 1
of probe, and 25ml of TaqMan Universal PCR Master Mix (ABI), in
a final volume of 50ml. The cDNA was subjected to 50 cycles of a
two-step PCR consisting of a 15-s denaturation step at 951C and a
1-min combined annealing/extension step at 601C. Plasmids were
diluted in a precise series, ranging from 5pg to 0.005fg (2 10
6 to
2 copies). For normalisation of each target in the samples, the copy
number of glyceraldehyde-3 phosphate dehydrogenase (GAPDH)
was used as an internal control. Maspin and GAPDH expression
levels (copy number) were calculated from standard curves using
each plasmid. The normalised values of maspin mRNA were
expressed as the ratio of maspin copy number per copy number of
GAPDH.
Immunohistochemistry
Tumour specimens and lymph nodes from 85 patients were fixed
with 10% buffered formalin and embedded in paraffin. Patient
characteristics are shown in Table 2. Tissue blocks were then sliced
into 4-mm sections and mounted on glass slides. The sections were
pretreated in 10mM citrate buffer (pH 6) by a microwave-based
antigen-retrieval method for 15min and then incubated overnight
with monoclonal anti-human maspin antibody (Pharmingen
Table 1 Patient characteristics for tissue analysis by DNA microarray
a
Gender Lymph node metastasis
b
Male 11 N0 5
Female 10 N1 11
Age (years) N2 4
38B85 (Avg: 61) N3 1
Peritoneal metastasis
c Histologic type
d
P0 14 tub1 4
P1 7 tub2 3
por1 7
Cytology
e por2 5
CY0 19 sig 1
CY1 2 ads 1
Hepatic metastasis
f
H0 20
H1 1 Stage
Ia 2
Depth of invasion
g Ib 3
T1 2 II 2
T2 7 IIIa 3
T3 11 IIIb 2
T4 1 IV 9
aPatient characteristics were determined according to the Japanese Classification of
Gastric Carcinoma (2nd edition).
bN0, none; N1, metastasis to Group 1 lymph nodes;
N2, metastasis to Group 2 lymph nodes; N3, metastasis to Group 3 lymph nodes.
cP0, absent; P1, present.
dtub1, well-differentiated tubular adenocarcinoma; tub2,
moderately differentiated tubular adenocarcinoma; por1, poorly differentiated
adenocarcinoma (solid type); por2, poorly differentiated adenocarcinoma (non-solid
type); sig, signet-ring cell carcinoma; ads, adenosquamous carcinoma.
eCytology in
peritoneal washings; CY0, negative; CY1, positive.
fH0, absent; H1, present.
gT1,
within mucosa or submucosa; T2, until muscularis propria or subserosa; T3,
penetration of serosa; T4, invasion of adjacent structures.
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sInternational, San Diego, CA, USA) at a dilution of 1:50. The
Histofine SAB-PO kit (Nichirei, Tokyo, Japan) was used to
visualise the antibody binding. Stained slides were reviewed and
graded by two pathologists by following a blind protocol
(observers had no information on clinicopathologic data). The
incidence of maspin-positive cells was graded as: 0, negative; 1þ,
o20%; 2þ, 20–80%; 3þ, 480%. Similarly, the relative staining
intensities of tumour cells were graded as: 0, negative; 1þ, weak;
2þ, moderate; 3þ, strong.
Statistical analysis
For microarray analysis, all values were analysed by using the
Mann–Whitney U-test or one-way analysis of variance (ANOVA)
following Dunnett’s t-test. A P-values lower than 0.01 were
considered to be statistically significant. For histochemistry,
Fischer’s exact probability test and the w
2 test were used for
testing the correlation between maspin protein expression and
clinicopathologic factors. Statistical differences were evaluated
between two groups with the Mann–Whitney test, and for three or
more groups with the Kruskal–Wallis test. A P-value of less than
0.05 was considered to be statistically significant.
RESULTS
Commonly upregulated genes in gastric cancer by DNA
microarray
We first applied a hierarchical clustering algorithm separately to
the samples and genes by using the measure of similarity and
average linkage clustering (Eisen et al, 1998) and found that
tumour and normal tissues were divided into different groups
(data not shown). We next searched for genes that are commonly
upregulated or downregulated in gastric cancer. Fold change (FC)
values of gene expression in the tumour tissue were calculated by
comparison with the pool data of six independent normal tissues.
We set the cutoff level of mean FC (MFC) at more than 4 or less
than 0.25, and applied Mann–Whitney’s U-test to identify genes
that were differentially expressed between cancer and normal
tissue. As a result, we found that 25 genes were upregulated and
two genes were downregulated in cancer tissue (Po0.01) (Table 2).
Genes associated with lymph node metastasis
To identify genes associated with lymph node metastasis, we
further compared gene expression profiles among six normal
tissues, 16 cancers with lymph node metastasis, and five cancers
without lymph node metastasis with respect to 27 genes (Table 3).
Three genes showed significantly higher expression in cancers with
metastasis than in those without metastasis (Table 4). If patients
with hepatic or peritoneal metastasis were excluded, only maspin
demonstrated significantly higher expression in cancers with
lymph node metastasis than in those without it (P¼0.0066).
We further investigated the expression of maspin by using RQ-
PCR and immunohistochemistry.
RQ-PCR for maspin mRNA
To verify the reliability of DNA microarray analysis, we
investigated the maspin mRNA expression level by RQ-PCR and
compared the results with the signal intensity obtained from DNA
microarray analysis for six samples from normal epithelium and
21 samples from gastric cancer. There was a significant correlation
between the signal intensity of maspin and the maspin mRNA
expression levels determined by RQ-PCR (Figure 1).
Immunohistochemistry of maspin
Immunohistochemistry was performed for a total of 85 patients
including the 21 patients whose tissue samples were analysed by
DNA microarray. Subcellular localisation of maspin protein was
observed in both the cytoplasm and membrane (Figure 2B–D).
Cells with nuclear localisation were extremely rare. A total of 78
cases displayed epithelium with intestinal metaplasia. Dense
immunoreactivity was observed in the epithelium with intestinal
metaplasia. Gastric normal epithelium without intestinal metapla-
sia showed no diffuse and dense immunoreactivity (Figure 2A).
Maspin expression was observed in 74 of 85 samples (87%) from
gastric cancer. Diffuse expression of maspin protein was observed
in 43 of 85 samples (51%) and, the expression was relatively strong
in 59 of 85 samples (69%). There was no significant correlation
between maspin protein expression and clinicopathologic features
such as depth of tumour invasion, hepatic or peritoneal metastasis,
and histological type. When patients with peritoneal or hepatic
metastasis were excluded, however, the incidence of maspin
protein expression was significantly higher in tumours accom-
panied with lymph node metastasis (Table 5). We also examined
immunoreactivities of metastatic tumour cells in 41 cases with
lymph node metastasis. Five of the 41 cases with lymph node
metastasis showed no positive immunoreactivity for maspin in the
primary tumours. In four of these five cases, there was no positive
Table 2 Patient characteristics for tissue analysis by immunohistochem-
istry
a
Gender Lymph node metastasis
b
Male 11 N0 41
Female 29 N1 24
Age (years) N2 15
18–86 (Avg: 68) N3 5
Peritoneal metastasis
c Histologic type
d
P0
P1 16 pap 3
tub1 25
tub2 19
Cytology
e
CY0
CY1 9 por1 17
por2 13
sig 4
Hepatic metastasis
f
H0
H1 7 muc 3
ads 1
Depth of invasion
g
T1 30
T2 27 Stage 30
T3 24 Ia 11
T4 4 Ib 10
II 4
IIIa 5
IIIb 25
IV
aPatient characteristics were determined according to the Japanese Classification of
Gastric Carcinoma (2nd edition).
bN0, none; N1, metastasis to Group 1 lymph nodes;
N2, metastasis to Group 2 lymph nodes; N3, metastasis to Group 3 lymph nodes.
cP0, absent; P1, present.
dpap, papillary adenocarcinoma; tub1, well-differentiated
tubular adenocarcinoma; tub2, moderately differentiated tubular adenocarcinoma;
por1, poorly differentiated adenocarcinoma (solid type); por2, poorly differentiated
adenocarcinoma (nonsolid type); sig, signet-ring cell carcinoma; muc, mucinous
adenocarcinoma; ads, adenosquamous carcinoma.
eCytology in peritoneal washings;
CY0, negative; CY1, positive.
fH0, absent; H1, present.
gT1, within mucosa or
submucosa; T2, until muscularis propria or subserosa; T3, penetration of serosa; T4,
invasion of adjacent structures.
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simmunoreactivity for maspin observed in the lymph node
metastasis as well. However, one (Case No. 10) of the five cases
exhibited positive staining for maspin in only the metastatic
lesions of its lymph nodes (Figure 3). In all 36 cases showed
positive staining in both primary and metastatic lesions.
DISCUSSION
For the purpose of seeking commonly upregulated genes in
specific tumour types, generally, a microdissection procedure is
used to separate the cancer cells and parenchymal cells. However,
gastric cancer tissue contains many parenchymal cells such as
fibroblasts, smooth muscle cells, and tumour-infiltrating mono-
nuclear cells, and there are numerous interactions between the
cancer cells and parenchymal cells of such substances as
angiogenesis inducing factor, growth regulatory cytokines, lectins,
and MMPs (Arias, 2001). For this reason, it is very important to
investigate the gene expression profiles not only in gastric cancer
cells but also in the accompanying parenchymal cells. Thus, we
Table 3 Genes commonly upregulated and downregulated in gastric cancers
Accession ID
a Gene name Normal Tumour MFC
b P
c
Upregulated genes
AB000712 CPE-receptor 221.50 2204.38 9.95 2.10E-06
M18728 Nonspecific crossreacting antigen 241.22 2275.94 9.44 5.40E-03
M29540 Carcinoembryonic antigen 262.13 2364.40 9.02 1.66E-03
AJ238246 Sarcolectin 82.90 726.15 8.76 2.82E-03
D78611 MEST 45.57 399.95 8.76 2.67E-03
U04313 Maspin 226.72 1693.48 7.47 9.47E-04
L17131 High mobility group protein (HMG-I(Y)) 307.70 1933.66 6.28 1.16E-05
AL031983 dJ271M21.6 (Diubiquitin) 286.75 1741.25 6.07 2.39E-03
AA156240 Homo sapiens cDNA 280.58 1691.72 6.03 1.82E-04
J03464 Collagen alpha-2 type I 518.23 2991.88 5.77 1.67E-03
X54942 ckshs2 170.18 968.87 5.69 1.76E-05
U73379 Cyclin-selective ubiquitin carrier protein 283.25 1525.39 5.39 1.66E-06
AA976838 oq35c12.s1 Homo sapiens cDNA 155.18 835.00 5.38 5.84E-03
J04088 DNA topoisomerase II (Top2) 208.87 1092.85 5.23 9.23E-03
D80008 KIAA0186 73.47 364.53 4.96 1.28E-03
AA203476 zx55e01.r1 Homo sapiens cDNA 131.52 646.47 4.92 2.77E-07
U55206 Gamma-glutamyl hydrolase (hGH) 74.68 327.58 4.39 6.20E-04
J04152 Gastrointestinal tumour-associated 483.73 2028.00 4.19 1.51E-05
Antigen GA733-1 protein
U97188 Putative RNA-binding protein KOC 58.85 246.36 4.19 2.35E-04
D11139 Tissue inhibitor of 1047.67 4334.40 4.14 5.03E-03
metalloproteinases
U28386 Nuclear localisation sequence 122.48 505.54 4.13 1.65E-06
receptor hSRP1 alpha
U97669 Notch3 123.62 510.09 4.13 4.11E-04
AB000714 hRVP1 194.80 788.65 4.05 4.22E-03
Downregulated genes
AB020629 KIAA0822 204.94 48.96 0.24 3.00E-4
AL050159 DKFZp586A0522 1940.37 434.71 0.224 1.89E-3
aGene bank accession ID.
bMFC, median fold change; tumour vs normal mucosa (T/N) gene expression values.
cCalculated by Mann–Whitney’s U-test.
Table 4 Genes with expression altered between node-positive (n¼16) and node-negative (n¼5) tumours
MFC
b
Accession ID
a Gene name Node-negative Node-positive P
c
U04313 Maspin 2.79 11.82 0.0019
M18728 Nonspecific crossreacting antigen 2.48 10.90 0.0157
M29540 Carcinoembryonic antigen 3.43 10.20 0.0295
aGene bank accession ID.
bMFC, mean fold change; tumour vs normal mucosa (T/N) gene expression values.
cCalculated by Mann–Whitney’s U-test.
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Figure 1 Correlation between relative signal intensities determined by
DNA microarray and mRNA expression levels determined by RQ-PCR.
Closed circles represent normal gastric epithelium (n¼6), and open circles
represent gastric cancer tissue (n¼21).
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sevaluated the gene expression profiles in gastric cancer with
stromal cells as a whole.
It has been reported that genes related to cell cycle regulation,
growth factor, DNA synthesis, transcription factor, ubiquitin–
proteasome pathway, matrix metalloproteinases, and angiogenesis-
inducing factor are commonly upregulated in gastric cancer, as
evidenced by using microarray technology (Hasegawa et al, 2002;
Hippo et al, 2002; Inoue et al, 2002). In the present study, we also
demonstrated the upregulation of previously reported genes such
as Topo II, cdc28 protein kinase2, TIMP, collagen alpha-2 type I,
Diubiquitin, and cyclin-selective ubiquitin carrier protein. We also
observed the upregulation of genes for previously well-known
tumour antigens overexpressed in gastric cancer carcinoembryo-
nic antigen (CEA) and nonspecific crossreacting antigens (NCAs).
Furthermore, we detected the upregulation of several interesting
genes that have not been reported as being expressed in gastric
cancer, such as CPE-R, Rvp.1, sarcolectin, KOC, Notch3, and
maspin.
Among the upregulated genes, CEA, NCA, and maspin were
selected as genes related to lymph node metastasis in the present
study. CEA is also well known as a tumour marker in gastric
cancer. It has been reported that serum levels and tissue
expression of this protein correlate with evidence of tumour
progression, such as lymph node metastasis, in keeping with our
results (Kojima et al, 1984; Nakane et al, 1994; Kim et al, 2000).
Nonspecific crossreacting antigen is a member of the CEA family
Figure 2 Immunohistochemistry for maspin protein. (A) High power view of gastric normal foverolar epithelium (scale bar¼100mm). Immunoreactivity
for maspin is negative. (B–D) High power view of maspin-positive gastric cancers (scale bar¼100mm). Subcellular localisation of maspin protein is
observed in cytoplasm and membrane (B–D). (B) (Case No. 24) and (C) (Case No. 32) are moderately differentiated tubular adenocarcinomas, and (D)
(Case No. 14) is a poorly differentiated adenocarcinoma, solid type. (E) High power view of maspin-negative gastric cancers (Case No. 10; scale
bar¼100mm).
Table 5 Correlation between lymph node metastasis and imunohisto-
chemistry for maspin protein in 65 patients without distant metastasis
Tumour
Number of
patients
Incidence of maspin-
positive cells
0123
Node-negative 41 6 4 15 16 P¼0.0133
a
Node-positive 24 1 2 2 19
aw
2 test.
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sand the specific upregulation of its mRNA or protein in cancer
tissue compared with that in normal mucosa in gastric cancer,
especially in well-differentiated adenocarcinoma, has been re-
ported (Kodera et al, 1993; Kinugasa et al, 1998). There is no
report, however, indicating a positive correlation between the
expression of NCA and evidence of tumour progression such as
lymph node metastasis. Although this is the first report describing
the role of NCA in lymph node metastasis, because the number of
patients was limited, further investigations to elucidate the role of
NCA in tumour progression should be carried out.
Maspin is a serine protease inhibitor belonging to the serpin
family. The maspin gene was originally identified in normal human
breast epithelium as encoding a 42kDa cytoplasmic protein, and is
known to have tumour suppressive activity attributable to the
inhibition of breast cancer cell motility, invasion, and metastasis
(Sheng et al, 1994; Zou et al, 1994; Seftor et al, 1998). Similarly, the
tumour suppressive activity of maspin has been demonstrated for
prostate cancer (Umekita et al, 1997), oral carcinoma (Xia et al,
2000), and colon cancer (Song et al, 2002). The prognostic
significance of maspin has also been demonstrated in breast cancer
(Seftor et al, 1998) and squamous cell carcinoma of the oral cavity
(Xia et al, 2000). On the contrary, overexpression of maspin was
observed in pancreatic (Maass et al, 2001) and ovarian cancer
(Sood et al, 2002). In the pancreas and ovary, maspin expression
was not detected in normal epithelium; however, it was detected in
cancer tissues, especially those with aggressive properties.
Recently, Heighway et al (2002) also reported that maspin, as well
as S100A2, was selected as an overrepresented gene in non-small-
cell lung cancer by using cDNA microarray. Little has been
reported on the role of maspin in gastric cancer. Son et al (2002)
first investigated maspin expression by using immunohistochem-
istry and RT–PCR. They reported that 90% of carcinoma tissues
showed immunoreactivity for maspin, and mRNA expression of
maspin was significantly higher in gastric adenocarcinoma than in
the gastric normal epithelium. They also fund that gastric epithelial
cells with intestinal metaplasia showed positive staining for
maspin. We had also previously reported that maspin expression
was observed in 80% of gastric cancers, in all normal epithelia with
intestinal metaplasia, but not in normal epithelium without
intestinal metaplasia (Akiyama et al, 2003). In the present study,
overexpression of maspin in carcinoma tissue compared with that
of normal epithelium was also observed by using oligonucleotide
microarray analysis, supporting the results of previous reports.
The results of microarray analysis were verified by RQ-PCR. There
was a strong correlation between the signal intensity of maspin
determined by DNA microarray and the maspin mRNA levels
determined by RQ-PCR, suggesting the high reliability of
oligonucleotide microarray. The role of maspin in tumour
development and progression in gastric cancer was further
investigated by immunohistochemistry. As previously reported,
maspin immunoreactivity was obtained in 87% of carcinoma
tissues and in most of normal epithelium with intestinal
metaplasia; however, none of the normal epithelium samples
without intestinal metaplasia showed positive immunoreactivity to
maspin protein. In addition, there was a significant correlation
between the immunoreactivity of maspin and the quantity of
maspin mRNA expression determined by oligonucleotide micro-
array and RQ-PCR (data not shown).
Concerning the correlation between maspin expression and
clinicopathologic features, we obtained significantly higher ex-
pression of maspin in tumours with lymph node metastasis than in
those without metastasis. Although overexpression of maspin is
present in the pancreas (Maass et al, 2001), ovary (Xia et al, 2000),
gastric (Son et al, 2002) and non-small-cell lung cancer (Heighway
et al, 2002), there have been no reports describing a positive
correlation of the maspin mRNA expression and lymph node
metastasis. Thus, this is the first report to demonstrate a
correlation between maspin expression and lymph node metas-
tasis. The role of maspin in lymph node metastasis was further
verified by using immunohistochemistry; the positive correlation
was observed between maspin expression and lymph node
metastasis in a subgroup of patients without distant metastasis.
This result indicates a more direct evidence for the role of maspin
in lymph node metastasis, because other metastatic pathways such
as haematological metastasis and peritoneal metastasis had been
excluded in this subgroup. In addition, in some patients, maspin
was upregulated only in the metastatic foci in lymph nodes, while
maspin expression was negative in the primary region. Thus, there
is a possibility that expression of maspin is regulated by an
epigenetic event that is differently represented in different organs.
Recently, Kim et al (2004) reported that the presence of
cytoplasmic maspin was correlated with lower tumour stage and
less lymph node involvement in lung cancers other than squamous
cell carcinoma. The contradictory results may derive from
different regulation mechanisms in different organs.
The regulation mechanism for maspin function is not fully
elucidated. The loss of maspin gene expression with increasing
malignancy is reportedly regulated at the transcriptional level in
Figure 3 Immunohistochemistry for maspin protein in metastatic tumour cells of a lymph node (Case No. 10). (A) Low power view of a lymph node
(Scale bar¼100mm). Nests of metastatic tumour cells are observed in the lymph node periphery. (B) High power view of a metastatic lesion (scale
bar¼100mm). Focal and dense immunoreactivity is observed.
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sbreast cancer (Domann et al, 2000). Recent studies have reported
on the roles of cytosine methylation and chromatin condensation
in the downregulation of maspin expression during neoplastic
progression (Maass et al, 2002). We had previously reported that
the maspin gene promoter region of all normal epithelia without
intestinal metaplasia was hypermethylated on both alleles, whereas
those regions with intestinal metaplasia frequently represented the
haploid type of hypomethylation status, and demethylation
frequently occurred and extended to both alleles in gastric cancer.
This suggests that demethylation at the maspin gene promoter
disrupts the cell-type-specific gene repression in both normal
epithelium and gastric cancer (Akiyama et al, 2003).
In conclusion, DNA microarray technology is thought to
be a useful tool for identifying specific genes correlated with
tumour progression in gastric cancer. Maspin, which was
selected as a lymph node metastasis-related gene by using DNA
microarray analysis, is upregulated in most gastric cancer tissues,
and this gene is supposed to have a potential role in lymph node
metastasis.
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